Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time brain-computer interface control of walking exoskeleton with bilateral sensory feedback.

Brain stimulation·2026
Same author

Deep Learning for the Prediction of Treatment Responses in Individuals With Epilepsy: Can We Get to Seizure Freedom Faster?

Neurology·2025
Same author

Driving in people with seizures and epilepsy.

The Lancet. Neurology·2025
Same author

Improving the tolerability of antiseizure medications: When and how to use cenobamate and other new antiseizure medications.

Epilepsia·2025
Same author

Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement.

Neurology·2025
Same author

Early feasibility of an embedded bi-directional brain-computer interface for ambulation.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

Related Experiment Video

Updated: Jul 4, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Generic antiepileptic drugs.

Susan J Shaw1, Gregory L Krauss

  • 1Gregory L. Krauss, MD Johns Hopkins School of Medicine, Meyer 2-147, 600 North Wolfe Street, Baltimore, MD 21287, USA. gkrauss@jhmi.edu.

Current Treatment Options in Neurology
|June 27, 2008
PubMed
Summary

Generic antiepileptic drugs (AEDs) offer cost savings but may require careful monitoring. Current FDA bioequivalence standards might not ensure safety for all epilepsy patients, especially with narrow therapeutic ratio drugs.

Area of Science:

  • Pharmacology and Pharmaceutics
  • Drug Regulation and Policy

Background:

  • Generic antiepileptic drugs (AEDs) are cost-effective alternatives to brand-name medications.
  • The US Food and Drug Administration (FDA) mandates bioequivalence, dissolution, and quality standards for generic drug approval.

Purpose of the Study:

  • To evaluate the adequacy of current FDA bioequivalence standards for generic AEDs.
  • To assess the safety and efficacy of generic AEDs in various patient populations.

Main Methods:

  • Bioequivalence is typically assessed via pharmacokinetic studies in healthy adults using single doses.
  • FDA standards require test drug C(max) and AUC ratios to be within 80%-125% of the reference drug with a 90% confidence interval.

Main Results:

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

Related Experiment Videos

Last Updated: Jul 4, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

  • Most generic AEDs meet FDA standards and are safe for most patients.
  • Bioequivalence has not been adequately evaluated in epilepsy patients, special populations, or those on multiple AEDs.
  • Generic-to-generic switches lack demonstrated safety and may cause significant drug concentration changes.

Conclusions:

  • While generally safe, current FDA bioequivalence standards may be insufficient for certain AEDs and patient groups.
  • Vulnerable patients require close monitoring during transitions to generic AEDs.
  • Further large-scale studies are needed to validate FDA bioequivalence standards for AEDs.